Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application phenoxybenzamine hydrochloride capsules 10mg. Aurobindo Pharma’s phenoxybenzamine hydrochloride capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Dibenzyline Capsules manufactured by Concordia Pharmaceuticals.
Phenoxybenzamine hydrochloride capsules, are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating.
Phenoxybenzamine hydrochloride capsules, has an estimated market size of US $7.4 million for the twelve months ending March 2023, as per IQVIA.
